Datopotamab Deruxtecan, often abbreviated as DATO, represents the significant advancement in targeted cancer therapy. This innovative antibody-drug conjugate combines the monoclonal immunoglobulin specifically focused on HER2 positive expressing cells with an potent anticancer payload, deruxtecan. The mechanism of action entails the antibody's capa